Home/Rokote Laboratories/Erkko Ylösmäki

EY

Erkko Ylösmäki

CEO

Rokote Laboratories

Therapeutic Areas

Infectious Diseases Respiratory Diseases

Rokote Laboratories Pipeline

Drug	Indication	Phase
FINVAC COVID-19	COVID-19 (SARS-CoV-2)	Phase 1
FINVAC Platform	Influenza, RSV, Tuberculosis, other respiratory pathogens	Pre-clinical

Leadership Team at Rokote Laboratories

Head of Clinical Trial Operations

Head of Vaccine Immunity

View full Rokote Laboratories profile